NCT01023217View on ClinicalTrials.gov

Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

July 31, 2012

Study Completion Date

September 30, 2012

Conditions
Hepatitis B, Chronic
Interventions
DRUG

Adefovir

Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks

DRUG

Entecavir

Entecavir 1 mg/day orally

DRUG

Lamivudine

Lamivudine (Zeffix) 100 mg/day orally

Trial Locations (1)

138-736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER